Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.
Newsletter
Stay up to date on practice-changing data in community practice.